68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors
- 14 September 2007
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 35 (1), 72-79
- https://doi.org/10.1007/s00259-007-0587-y
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Imaging of Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Method for transforming CT images for attenuation correction in PET/CT imagingMedical Physics, 2006
- Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Validation of GATE Monte Carlo simulations of the GE Advance/Discovery LS PET scannersMedical Physics, 2005
- 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5European Journal of Nuclear Medicine and Molecular Imaging, 2004
- Performance evaluation of the new whole-body PET/CT scanner: Discovery STEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targetingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotideEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HClThe International Journal of Applied Radiation and Isotopes, 1981